Advances in immune checkpoint inhibitor combined with other treatment methods for hepatocellular carcinoma
10.3969/j.issn.1001-5256.2020.06.043
- VernacularTitle:免疫检查点抑制剂联合治疗肝癌的进展
- Author:
Tao SUN
1
;
Yanqiao REN
;
Yanyan CAO
;
Chuansheng ZHENG
Author Information
1. Department of Radiology, Union Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan 430022, China
- Publication Type:Research Article
- Keywords:
liver neoplasms;
immunosuppressive agents;
drug therapy, combination
- From:
Journal of Clinical Hepatology
2020;36(6):1386-1388
- CountryChina
- Language:Chinese
-
Abstract:
In recent years, immune checkpoint inhibitor (ICI) in the treatment of unresectable liver cancer has attracted great attention in China and foreign countries and great progress has been achieved, but ICI monotherapy cannot bring benefits to most patients with liver cancer. Therefore, it is a new trend to explore the combination of ICI with other treatment methods. This article summarizes the advances in ICI combination therapy for unresectable liver cancer in China and foreign countries, including ICI combined with molecular targeted therapy, PD-1/PD-L1 inhibitor combined with CTLA-4 inhibitor, and ICI combined with local therapy. The results show that for patients with unresectable liver cancer, ICI combined with other treatment methods has a significantly better effect than ICI monotherapy; however, further studies are needed to explore which treatment method combined with ICI can bring the greatest benefits to patients.
